Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TMCnet News [October 16, 2026] | / | Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) - Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA(R) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to two newly hired employees. Korro granted the new employees nonstatutory stock options to purchase 4,000 shares of Korro's common stock, in the aggregate, at an exercise price of $8.88 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, October 14, 2026. The options each have a ten-year term and vest over four years, with 25% of the shares vesting on the first anniversary of each such employee's applicable start date and the remaining 75% vesting in 36 equal monthly installments on each monthly anniversary thereafter until the fourth anniversary of such employee's applicable start date, subject to the employee's continued service with Korro through each applicable vesting date. These grants were approved by Korro's independent Compensation Committee pursuant to Korro's 2026 Inducement Plan and were made as an inducement material to the employee's acceptance of employmnt with Korro in accordance with Nasdaq Listing Rule 5635(c)(4). About Korro Korro is a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA(R) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of RNA-editing oligonucleotides (REOs) that modify the targeted native mRNA transcript to repair or form a de novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of REOs, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology. As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an REO-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutaneous administration, manufacturing know-how, and established regulatory pathways of approved oligonucleotide medicines. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com. Korro Bio Contact Information Investor & Media Contact Malini Chatterjee, Ph.D Blueprint Life Science Group [email protected] or [email protected] 917.330.4269 [ Back To TMCnet.com's Homepage] |

Korro Bio reports inducement grant under Nasdaq Listing Rule 5635(c)(4). CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) - Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA(R) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee. Korro granted the new employee a nonstatutory stock option to purchase 600 shares of Korro's common stock at an exercise price of $13.35 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, August 12, 2026. The option has a ten-year term and vests over four years, with 25% of the shares vesting on the first anniversary of the employee's start date and the remaining 75% vesting in 36 equal monthly installments on each monthly anniversary thereafter until the fourth anniversary of the employee's start date, subject to the employee's continued service with Korro through each applicable vesting date. This grant was approved by Korro's independent Compensation Committee pursuant to Korro's 2026 Inducement Plan and was made as an inducement material to the employee's acceptance of employment with Korro in accordance with Nasdaq Listing Rule 5635(c)(4). About Korro Korro is a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA(R) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of oligonucleotides that modify the targeted native mRNA transcript to repair or form a de-novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of oligonucleotides, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology. As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutaneous administration, manufacturing know-how, and established regulatory pathways of approved oligonucleotide medicines. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com. Korro Bio Contact Information Investor & Media Contact Malini Chatterjee, Ph.D Blueprint Life Science Group [email protected] or [email protected] 917.330.4269

Korro Bio (NASDAQ:KRRO) releases quarterly earnings results, beats expectations by $0.22 EPS. August 8, 2026 Key points. * Korro Bio beat quarterly earnings expectations: The clinical-stage biotech reported a loss of $1.07 per share, $0.22 better than analysts' forecast, while revenue of $1.50 million exceeded expectations of $0.21 million. However, it posted a negative 1,834.48% net margin and negative 118.45% return on equity. * Shares rose but remain highly volatile: KRRO gained $1.13 to $13.25, compared with a 52-week range of $5.20 to $55.89. Analysts maintain a "Moderate Buy" consensus with a $16.71 average price target. * Insiders have been selling shares: Company insiders sold 306,026 shares worth approximately $4.31 million over the past 90 days, while institutional investors and hedge funds own 13.18% of the stock. * Five stocks to consider instead of Korro Bio. Korro Bio (NASDAQ:KRRO - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($1.07) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.22, FiscalAI reports. The company had revenue of $1.50 million for the quarter, compared to analysts' expectations of $0.21 million. Korro Bio had a negative return on equity of 118.45% and a negative net margin of 1,834.48%. Korro Bio price performance. Shares of NASDAQ:KRRO traded up $1.13 during trading hours on Friday, hitting $13.25. 120,198 shares of the company's stock traded hands, compared to its average volume of 159,064. The business has a fifty day moving average price of $12.19 and a 200-day moving average price of $12.06. Korro Bio has a 1 year low of $5.20 and a 1 year high of $55.89. The firm has a market capitalization of $191.06 million, a P/E ratio of -1.32 and a beta of 3.04. Analyst ratings changes. KRRO has been the topic of a number of analyst reports. Lifesci Capital raised Korro Bio to a "strong-buy" rating in a research report on Friday, May 29th. JonesTrading upgraded Korro Bio from a "hold" rating to a "strong-buy" rating in a research note on Friday, May 8th. HC Wainwright reduced their price objective on Korro Bio from $20.00 to $15.00 and set a "buy" rating for the company in a research note on Tuesday, May 19th. Wall Street Zen upgraded shares of Korro Bio from a "strong sell" rating to a "sell" rating in a research note on Saturday. Finally, Citigroup assumed coverage on Korro Bio in a report on Monday, May 18th. They set a "buy" rating and a $21.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $16.71. Insider activity at Korro Bio. In related news, Director Jean Francois Formela sold 9,323 shares of the business's stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $13.96, for a total value of $130,149.08. Following the completion of the transaction, the director owned 146,305 shares of the company's stock, valued at $2,042,417.80. The trade was a 5.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ram Aiyar sold 15,152 shares of the stock in a transaction on Friday, May 29th. The shares were sold at an average price of $12.98, for a total value of $196,672.96. Following the sale, the chief executive officer directly owned 74,848 shares in the company, valued at $971,527.04. This trade represents a 16.84% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 306,026 shares of company stock valued at $4,309,637 over the last ninety days. Company insiders own 4.80% of the company's stock. Institutional inflows and outflows. Hedge funds have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC purchased a new stake in shares of Korro Bio during the fourth quarter valued at $4,806,000. TCG Crossover Management LLC purchased a new stake in shares of Korro Bio in the third quarter worth about $19,937,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Korro Bio during the 3rd quarter worth approximately $4,319,000. Raymond James Financial Inc. grew its position in Korro Bio by 78.6% during the third quarter. Raymond James Financial Inc. now owns 148,971 shares of the company's stock valued at $7,134,000 after buying an additional 65,579 shares during the period. Finally, F m Investments LLC acquired a new stake in shares of Korro Bio during the 3rd quarter valued at about $2,646,000. 13.18% of the stock is owned by institutional investors and hedge funds. Korro Bio company profile. Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company's proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases. The company's pipeline features both engineered enzyme therapeutics and live biotherapeutics. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Korro Bio, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Korro Bio wasn't on the list. While Korro Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates.